Vanguard Portfolio Management’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Vanguard Portfolio Management's SMMT Position: Q3 2026 in Review
Vanguard Portfolio Management increased its Summit Therapeutics (SMMT) stake by 33% in Q3 2026, buying an estimated $25.1M and bringing the position to 6,717,642 shares worth $114M. The position accounts for 0.01% of the portfolio, ranked #1433.
Vanguard Portfolio Management first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Vanguard Portfolio Management held 6,717,642 shares of Summit Therapeutics worth $114M as of Q3 2026.
- Vanguard Portfolio Management bought 1,675,452 Summit Therapeutics shares in Q3 2026, an estimated $25.1M.
- Summit Therapeutics made up 0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1433 holding.
- Vanguard Portfolio Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.